Wang Yu-Tong, Zheng Sheng-Yuan, Jiang Shi-de, Luo Yan, Wu Yu-Xiang, Naranmandakh Shinen, Li Yu-Sheng, Liu Shu-Guang, Xiao Wen-Feng
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Clinical Medicine, Xiangya Medicine School, Central South University, Changsha, Hunan, China.
Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Pharmacol Res. 2024 Dec;210:107480. doi: 10.1016/j.phrs.2024.107480. Epub 2024 Oct 25.
Degenerative musculoskeletal diseases are a class of diseases related to the gradual structural and functional deterioration of muscles, joints, and bones, including osteoarthritis (OA), osteoporosis (OP), sarcopenia (SP), and intervertebral disc degeneration (IDD). As the proportion of aging people around the world increases, degenerative musculoskeletal diseases not only have a multifaceted impact on patients, but also impose a huge burden on the medical industry in various countries. Therefore, it is crucial to find key regulatory factors and potential therapeutic targets. Recent studies have shown that irisin plays an important role in degenerative musculoskeletal diseases, suggesting that it may become a key molecule in the prevention and treatment of degenerative diseases of the musculoskeletal system. Therefore, this review provides a comprehensive description of the release and basic functions of irisin, and summarizes the role of irisin in OA, OP, SP, and IDD from a cellular and tissue perspective, providing comprehensive basis for clinical application. In addition, we summarized the many roles of irisin as a key information molecule in bone-muscle-adipose crosstalk and a regulatory molecule involved in inflammation, senescence, and cell death, and proposed the interesting possibility of irisin in degenerative musculoskeletal diseases.
退行性肌肉骨骼疾病是一类与肌肉、关节和骨骼的结构和功能逐渐退化相关的疾病,包括骨关节炎(OA)、骨质疏松症(OP)、肌肉减少症(SP)和椎间盘退变(IDD)。随着全球老龄化人口比例的增加,退行性肌肉骨骼疾病不仅对患者产生多方面影响,也给各国医疗行业带来巨大负担。因此,找到关键调控因子和潜在治疗靶点至关重要。最近的研究表明,鸢尾素在退行性肌肉骨骼疾病中发挥重要作用,这表明它可能成为预防和治疗肌肉骨骼系统退行性疾病的关键分子。因此,本综述全面描述了鸢尾素的释放及其基本功能,并从细胞和组织角度总结了鸢尾素在OA、OP、SP和IDD中的作用,为临床应用提供全面依据。此外,我们总结了鸢尾素作为骨-肌肉-脂肪相互作用中的关键信息分子以及参与炎症、衰老和细胞死亡的调节分子的多种作用,并提出了鸢尾素在退行性肌肉骨骼疾病中的有趣可能性。
Ann N Y Acad Sci. 2017-4-24
Biomed Pharmacother. 2023-12-31
Front Endocrinol (Lausanne). 2023
J Biol Regul Homeost Agents. 2020
Oxid Med Cell Longev. 2022
Front Endocrinol (Lausanne). 2025-2-4
J Funct Morphol Kinesiol. 2025-8-8
J Orthop Translat. 2025-6-5
BMC Musculoskelet Disord. 2025-5-27